Emerging evidence for CHFR as a cancer biomarker: From tumor biology to precision medicine

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 161-171

  Derks, Sarah ^a   Cleven, Arjen H G ^b   Melotte, Veerle ^b   Smits, Kim M ^b   Brandes, Johann C ^c   Azad, Nilofer ^f   Van Criekinge, Wim ^d,e   De Bruïne, Adriaan P ^b   Herman, James G ^f   Van Engeland, Manon ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GHENT UNIVERSITY   (Belgium)

^e MDxHealth   (Belgium)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CHFR promoter methylation; Predictive biomarker; Taxane sensitivity

Indexed keywords

CHECKPOINT WITH FORKHEAD AND RING FINGER DOMAIN PROTEIN; PROTEIN TYROSINE PHOSPHATASE; TAXANE DERIVATIVE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CHFR PROTEIN, HUMAN; TUMOR PROTEIN;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER THERAPY; CELL CYCLE REGULATION; CHEMOSENSITIVITY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; G2 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; M PHASE CELL CYCLE CHECKPOINT; METAPHASE; MICROTUBULE; MULTIPLE CANCER; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; GENETICS; METABOLISM; NEOPLASMS; PROGNOSIS;

CELL CYCLE PROTEINS; CPG ISLANDS; DNA METHYLATION; HUMANS; MODELS, GENETIC; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84899984093     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9462-4     Document Type: Review

References (88)

1. Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013). Genomic medicine frontier in human solid tumors: prospects and challenges. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(15), 1874-1884.
2. Olopade, O. I., Grushko, T. A., Nanda, R., & Huo, D. (2008). Advances in breast cancer: pathways to personalized medicine. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 14(24), 7988-7999.
3. Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., Leong, S. S., Sriuranpong, V., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(21), 2866-2874.
4. Mok, T. S. (2011). Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology, 8(11), 661-668.
5. Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., et al. (2011). Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology, 12(11), 1004-1012.
6. Andre, F., & Zielinski, C. C. (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 23(Suppl 6), vi46-vi51.
7. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine, 359(17), 1757-1765.
8. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine, 363(9), 809-819.
9. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997-1003.
10. Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., et al. (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology, 26(25), 4189-4199.
11. Scolnick, D. M., & Halazonetis, T. D. (2000). Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature, 406(6794), 430-435.
12. Shtivelman, E. (2003). Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR. Molecular Cancer Research: MCR, 1(13), 959-969.
13. Daniels, M. J., Marson, A., & Venkitaraman, A. R. (2004). PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein. Nature Structural & Molecular Biology, 11(11), 1114-1121.
14. Fukuda, T., Kondo, Y., & Nakagama, H. (2008). The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain. PLoS ONE, 3(3), e1776.
15. Kim, J. S., Park, Y. Y., Park, S. Y., Cho, H., & Kang, D. (2011). The auto-ubiquitylation of E3 ubiquitin-protein ligase Chfr at G2 phase is required for accumulation of polo-like kinase 1 and mitotic entry in mammalian cells. The Journal of Biological Chemistry, 286(35), 30615-30623.
16. Yarm, F. R. (2002). Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Molecular and Cellular Biology, 22(17), 6209-6221.
17. Burgess, A., Labbe, J. C., Vigneron, S., Bonneaud, N., Strub, J. M., Van Dorsselaer, A., et al. (2008). Chfr interacts and colocalizes with TCTP to the mitotic spindle. Oncogene, 27(42), 5554-5566.
18. van Vugt, M. A., & Medema, R. H. (2005). Getting in and out of mitosis with Polo-like kinase-1. Oncogene, 24(17), 2844-2859.
19. Li, J., Williams, B. L., Haire, L. F., Goldberg, M., Wilker, E., Durocher, D., et al. (2002). Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Molecular Cell, 9(5), 1045-1054.
20. Yu, X., Minter-Dykhouse, K., Malureanu, L., Zhao, W. M., Zhang, D., Merkle, C. J., et al. (2005). Chfr is required for tumor suppression and Aurora A regulation. Nature Genetics, 37(4), 401-406.
21. Privette, L. M., Weier, J. F., Nguyen, H. N., Yu, X., & Petty, E. M. (2008). Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia, 10(7), 643-652.
22. Vader, G., & Lens, S. M. (2008). The Aurora kinase family in cell division and cancer. Biochimica et Biophysica Acta, 1786(1), 60-72.
23. Kang, D., Chen, J., Wong, J., & Fang, G. (2002). The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. The Journal of Cell Biology, 156(2), 249-259.
24. Summers, M. K., Bothos, J., & Halazonetis, T. D. (2005). The CHFR mitotic checkpoint protein delays cell cycle progression by excluding cyclin B1 from the nucleus. Oncogene, 24(16), 2589-2598.
25. Bothos, J., Summers, M. K., Venere, M., Scolnick, D. M., & Halazonetis, T. D. (2003). The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene, 22(46), 7101-7107.
26. Welchman, R. L., Gordon, C., & Mayer, R. J. (2005). Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nature Reviews Molecular Cell Biology, 6(8), 599-609.
27. Maddika, S., Sy, S. M., & Chen, J. (2009). Functional interaction between Chfr and Kif22 controls genomic stability. The Journal of Biological Chemistry, 284(19), 12998-13003.
28. Oh, Y. M., Kwon, Y. E., Kim, J. M., Bae, S. J., Lee, B. K., Yoo, S. J., et al. (2009). Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nature Cell Biology, 11(3), 295-302.
29. Kashima, L., Idogawa, M., Mita, H., Shitashige, M., Yamada, T., Ogi, K., et al. (2012). CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. The Journal of Biological Chemistry, 287(16), 12975-12984.
30. Vidal, A., & Koff, A. (2000). Cell-cycle inhibitors: three families united by a common cause. Gene, 247(1-2), 1-15.
31. Kim, J. H., Kim, B., Cai, L., Choi, H. J., Ohgi, K. A., Tran, C., et al. (2005). Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature, 434(7035), 921-926.
32. Ahel, I., Ahel, D., Matsusaka, T., Clark, A. J., Pines, J., Boulton, S. J., et al. (2008). Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature, 451(7174), 81-85.
33. Shinde, S. R., Gangula, N. R., Kavela, S., Pandey, V., & Maddika, S. (2013). TOPK and PTEN participate in CHFR mediated mitotic checkpoint. Cellular Signalling, 25(12), 2511-2517.
34. Matsusaka, T., & Pines, J. (2004). Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. The Journal of Cell Biology, 166(4), 507-516.
35. Fang, G., Yu, H., & Kirschner, M. W. (1998). The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes and Development, 12(12), 1871-1883.
36. Keller, J. A., & Petty, E. M. (2011). CHFR binds to and regulates MAD2 in the spindle checkpoint through its cysteine-rich domain. Biochemical and Biophysical Research Communications, 409(3), 389-393.
37. Bertholon, J., Wang, Q., Falette, N., Verny, C., Auclair, J., Chassot, C., et al. (2003). Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene, 22(55), 8956-8960.
38. Fu, Z., Regan, K., Zhang, L., Muders, M. H., Thibodeau, S. N., French, A., et al. (2009). Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. The Journal of Clinical Investigation, 119(9), 2714-2724.
39. Kashima, L., Toyota, M., Mita, H., Suzuki, H., Idogawa, M., Ogi, K., et al. (2009). CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene, 28(29), 2643-2653.
40. Nurnberg, W., Tobias, D., Otto, F., Henz, B. M., & Schadendorf, D. (1999). Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. The Journal of Pathology, 189(4), 546-551.
41. Lee, K. H., Bae, S. H., Lee, J. L., Hyun, M. S., Kim, S. H., Song, S. K., et al. (2004). Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology, 66(3), 210-217.
42. Mizuno, K., Osada, H., Konishi, H., Tatematsu, Y., Yatabe, Y., Mitsudomi, T., et al. (2002). Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene, 21(15), 2328-2333.
43. Kang, H. C., Kim, I. J., Jang, S. G., Hong, S. H., Hwang, J. A., Shin, H. R., et al. (2008). Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk. Cancer Letters, 260(1-2), 170-179.
44. Mariatos, G., Bothos, J., Zacharatos, P., Summers, M. K., Scolnick, D. M., Kittas, C., et al. (2003). Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Research, 63(21), 7185-7189.
45. Soutto, M., Peng, D., Razvi, M., Ruemmele, P., Hartmann, A., Roessner, A., et al. (2010). Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer, 116(17), 4033-4042.
46. Shibata, Y., Haruki, N., Kuwabara, Y., Ishiguro, H., Shinoda, N., Sato, A., et al. (2002). Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis, 23(10), 1695-1699.
47. Salazar, F., Molina, M. A., Sanchez-Ronco, M., Moran, T., Ramirez, J. L., Sanchez, J. M., et al. (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1), 84-91.
48. Bosch, L. J., Mongera, S., Terhaar Sive Droste, J. S., Oort, F. A., van Turenhout, S. T., Penning, M. T., et al. (2012). Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cellular Oncology, 35(4), 309-315.
49. Hiraki, M., Kitajima, Y., Sato, S., Nakamura, J., Hashiguchi, K., Noshiro, H., et al. (2010). Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World journal of gastroenterology: WJG, 16(3), 330-338.
50. Hiraki, M., Kitajima, Y., Koga, Y., Tanaka, T., Nakamura, J., Hashiguchi, K., et al. (2011). Aberrant Gene Methylation Is a Biomarker for the Detection of Cancer Cells in Peritoneal Wash Samples from Advanced Gastric Cancer Patients. Annals of surgical oncology.
51. Koga, T., Takeshita, M., Yano, T., Maehara, Y., & Sueishi, K. (2011). CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. International Journal of Cancer. Journal International du Cancer, 128(5), 1009-1017.
52. Koga, T., Takeshita, M., Ijichi, K., Yano, T., Maehara, Y., & Sueishi, K. (2013). CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes. Human pathology.
53. Takeshita, M., Koga, T., Takayama, K., Kouso, H., Nishimura-Ikeda, Y., Yoshino, I., et al. (2008). CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes. International Journal of Cancer. Journal International du Cancer, 123(7), 1623-1630.
54. Tanaka, M., Chang, P., Li, Y., Li, D., Overman, M., Maru, D. M., et al. (2011). Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 17(13), 4531-4540.
55. Chaturvedi, P., Sudakin, V., Bobiak, M. L., Fisher, P. W., Mattern, M. R., Jablonski, S. A., et al. (2002). Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Research, 62(6), 1797-1801.
56. Satoh, A., Toyota, M., Itoh, F., Sasaki, Y., Suzuki, H., Ogi, K., et al. (2003). Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Research, 63(24), 8606-8613.
57. Koga, Y., Kitajima, Y., Miyoshi, A., Sato, K., Sato, S., & Miyazaki, K. (2006). The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. Journal of Gastroenterology, 41(2), 133-139.
58. Yoshida, K., Hamai, Y., Suzuki, T., Sanada, Y., Oue, N., & Yasui, W. (2006). DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Research, 26(1A), 49-54.
59. Banno, K., Yanokura, M., Kawaguchi, M., Kuwabara, Y., Akiyoshi, J., Kobayashi, Y., et al. (2007). Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. International Journal of Oncology, 31(4), 713-720.
60. Yanokura, M., Banno, K., Kawaguchi, M., Hirao, N., Hirasawa, A., Susumu, N., et al. (2007). Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncology Reports, 17(1), 41-48.
61. Wang, X., Yang, Y., Xu, C., Xiao, L., Shen, H., Zhang, X., et al. (2011). CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. International Journal of Gynecological Cancer: official journal of the International Gynecological Cancer Society, 21(6), 996-1003.
62. Takeshita, M., Koga, T., Takayama, K., Yano, T., Maehara, Y., Nakanishi, Y., et al. (2010). Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer. Cancer Biology and Therapy, 10(9), 933-941.
63. Pillai, R. N., Brodie, S. A., Sica, G. L., Shaojin, Y., Li, G., Nickleach, D. C., et al. (2013). CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(6), 1603-1611.
64. Pelosof, L., Yerram, S. R., Ahuja, N., Delmas, A., Danilova, L., Herman, J. G., et al. (2013). CHFR silencing or microsatellite instability is associated with increased anti-tumor activity of docetaxel or gemcitabine in colorectal cancer. International Journal of Cancer. Journal International du Cancer
65. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., & Baylin, S. B. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America, 93(18), 9821-9826.
66. van Vlodrop, I. J., Niessen, H. E., Derks, S., Baldewijns, M. M., van Criekinge, W., Herman, J. G., et al. (2011). Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clinical Cancer Research: An Official journal of the American Association for Cancer Research, 17(13), 4225-4231.
67. Brandes, J. C., van Engeland, M., Wouters, K. A., Weijenberg, M. P., & Herman, J. G. (2005). CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis, 26(6), 1152-1156.
68. Tost, J., & Gut, I. G. (2007). DNA methylation analysis by pyrosequencing. Nature Protocols, 2(9), 2265-2275.
69. Simon, R. M., Paik, S., & Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute, 101(21), 1446-1452.
70. Privette, L. M., Gonzalez, M. E., Ding, L., Kleer, C. G., & Petty, E. M. (2007). Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Research, 67(13), 6064-6074.
71. Erson, A. E., & Petty, E. M. (2004). CHFR-associated early G2/M checkpoint defects in breast cancer cells. Molecular Carcinogenesis, 39(1), 26-33.
72. Agundez, M., Grau, L., Palou, J., Algaba, F., Villavicencio, H., & Sanchez-Carbayo, M. (2011). Evaluation of the methylation status of tumour suppressor genes for predicting bacillus calmette-guerin response in patients with T1G3 high-risk bladder tumours. European Urology, 60(1), 131-140.
73. Toyota, M., Sasaki, Y., Satoh, A., Ogi, K., Kikuchi, T., Suzuki, H., et al. (2003). Epigenetic inactivation of CHFR in human tumors. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7818-7823.
74. Corn, P. G., Summers, M. K., Fogt, F., Virmani, A. K., Gazdar, A. F., Halazonetis, T. D., et al. (2003). Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis, 24(1), 47-51.
75. Derks, S., Postma, C., Carvalho, B., van den Bosch, S. M., Moerkerk, P. T., Herman, J. G., et al. (2008). Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis, 29(2), 434-439.
76. Morioka, Y., Hibi, K., Sakai, M., Koike, M., Fujiwara, M., Kodera, Y., et al. (2006). Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer. Anticancer Research, 26(6B), 4267-4270.
77. Kawasaki, T., Ohnishi, M., Nosho, K., Suemoto, Y., Kirkner, G. J., Meyerhardt, J. A., et al. (2008). CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 21(3), 245-255.
78. Honda, T., Tamura, G., Waki, T., Kawata, S., Nishizuka, S., & Motoyama, T. (2004). Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. British Journal of Cancer, 90(10), 2013-2016.
79. Kang, H. C., Kim, I. J., Park, J. H., Shin, Y., Park, H. W., Ku, J. L., et al. (2004). Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncology Reports, 12(1), 129-133.
80. Cheung, H. W., Ching, Y. P., Nicholls, J. M., Ling, M. T., Wong, Y. C., Hui, N., et al. (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Molecular Carcinogenesis, 43(4), 237-245.
81. Hutajulu, S. H., Indrasari, S. R., Indrawati, L. P., Harijadi, A., Duin, S., Haryana, S. M., et al. (2011). Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Molecular Cancer, 10, 48.
82. Morioka, Y., Hibi, K., Sakai, M., Koike, M., Fujiwara, M., Kodera, Y., et al. (2006). Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Research, 26(3A), 1791-1795.
83. Sakai, M., Hibi, K., Kanazumi, N., Nomoto, S., Inoue, S., Takeda, S., et al. (2005). Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Hepato-Gastroenterology, 52(66), 1854-1857.
84. Tozawa, T., Tamura, G., Honda, T., Nawata, S., Kimura, W., Makino, N., et al. (2004). Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Science, 95(9), 736-740.
85. Ogi, K., Toyota, M., Mita, H., Satoh, A., Kashima, L., Sasaki, Y., et al. (2005). Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biology & Therapy, 4(7), 773-780.
86. Baba, S., Hara, A., Kato, K., Long, N. K., Hatano, Y., Kimura, M., et al. (2009). Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. Oncology Reports, 22(5), 1173-1179.
87. van Doorn, R., Zoutman, W. H., Dijkman, R., de Menezes, R. X., Commandeur, S., Mulder, A. A., et al. (2005). Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23(17), 3886-3896.
88. Chen, K., Sawhney, R., Khan, M., Benninger, M. S., Hou, Z., Sethi, S., et al. (2007). Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Archives of Otolaryngology-Head & Neck Surgery, 133(11), 1131-1138.